Pfizer and BioNTech to seek regulatory authorisation for Covid-19 booster dose
Pfizer and BioNTech believe that a third dose may be needed within six to 12 months after the…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
09 Jul 21
Pfizer and BioNTech believe that a third dose may be needed within six to 12 months after the…
08 Jul 21
Vyxeos belongs to the antineoplastics class of medicines, developed using the company’s CombiPlex technology platform
07 Jul 21
The announcement follows competition clearances in the US, Japan and other countries, pending regulatory approval in the UK
06 Jul 21
Lumevoq is authorised to treat patients with vision loss due to LHON caused by a mutation in the…
01 Jul 21
Rylaze is indicated for ALL/LBL in paediatric and adult patients, who have developed hypersensitivity to E. coli-derived asparaginase
30 Jun 21
Moderna’s Covid-19 vaccine is authorised in more than 50 countries and received Emergency Use Listing (EUL) from the…
29 Jun 21
The approval is based on results from Phase 3 SAkuraStar and SAkuraSky clinical trials of Enspryng in people…
28 Jun 21
The settlement facilitates the exclusion of J&J from a trial that is scheduled to start in Suffolk County…
25 Jun 21
The FDA authorisation allows emergency use of Actemra for the treatment of Covid-19 in hospitalised adult and paediatric…
25 Jun 21
Donanemab is an investigational antibody therapy that has shown positive results in treating Alzheimer's disease in clinical trials